Board MeetingJul 29, 2026, 08:31 AM
RenovoRx to Host Q2 2026 Financial Results Call on Aug 12
AI Summary
RenovoRx, Inc. announced it will host its second quarter 2026 financial results and business highlights conference call on August 12, 2026, at 4:30 p.m. ET. Management plans to discuss growing revenues from RenovoCath sales, increased adoption at U.S. cancer centers, and an update on the Phase III TIGeR-PaC clinical trial, which expects full enrollment soon and final data in mid-to-late 2027. The company also highlighted recent FDA Orphan Drug Designation for oxaliplatin in pancreatic cancer and continued expansion of its TAMP therapy platform.
Key Highlights
- RenovoRx to host Q2 2026 financial results and business highlights conference call on August 12, 2026.
- Management will discuss growing revenues from commercial sales of RenovoCath.
- Increased RenovoCath adoption at high-volume U.S. cancer centers and broader repeat orders.
- Full enrollment in Phase III TIGeR-PaC clinical trial expected in the very near future.
- Final data from TIGeR-PaC trial anticipated in mid-to-late 2027.
- Recent progress includes FDA Orphan Drug Designation for oxaliplatin in pancreatic cancer.
- RenovoCath sales were approximately $1.1 million in 2025 and $563,000 in Q1 2026.
Price Impact
More from RNXT